COVID-19 Vaccine: Where Are We Now and Where Should We Go?

Overview

Journal Expert Rev Vaccines

Date 2021 Jan 13

PMID 33435774

Citations 84

Authors

Saman Soleimanpour

Atieh Yaghoubi

Affiliations

Soon will be listed here.

Abstract

Introduction: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has currently caused the pandemic with a high progressive speed and has been considered as the global public health crisis in 2020. This new member of the coronavirus family has created a potentially fatal disease, called coronavirus disease-2019 (COVID-19). Despite the continuous efforts of researchers to find effective vaccines and drugs for COVID-19, there is still no success in this matter.

Areas Covered: Here, the literature regarding the COVID-19 vaccine candidates currently in the clinical trials, as well as main candidates in pre-clinical stages for development and research, were reviewed. These candidates have been developed under five different major platforms, including live-attenuated vaccine, mRNA-based vaccine, DNA vaccines, inactivated virus, and viral-vector-based vaccine.

Expert Opinion: There are several limitations in the field of the rapid vaccine development against SARS-CoV-2, and other members of the coronavirus family such as SARS-CoV and MERS-CoV. The key challenges of designing an effective vaccine within a short time include finding the virulence ability of an emerging virus and potential antigen, choosing suitable experimental models and efficient route of administration, the immune-response study, designing the clinical trials, and determining the safety, as well as efficacy.

Citing Articles

Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results.

Kutumbetov L, Myrzakhmetova B, Tussipova A, Zhapparova G, Tlenchiyeva T, Bissenbayeva K Vaccines (Basel). 2025; 12(12.

PMID: 39772061 PMC: 11728456. DOI: 10.3390/vaccines12121401.

A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.

Chavda V, Yadav D, Parmar H, Brahmbhatt R, Patel B, Madhwani K Curr Top Med Chem. 2024; 24(21):1883-1916.

PMID: 38859776 DOI: 10.2174/0115680266296095240529114058.

From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019.

Jin G, Wang R, Jin Y, Song Y, Wang T Clin Transl Immunology. 2024; 13(5):e1514.

PMID: 38770238 PMC: 11103645. DOI: 10.1002/cti2.1514.

Recent and advanced nano-technological strategies for COVID-19 vaccine development.

Nwagwu C, Ugwu C, Ogbonna J, Onugwu A, Agbo C, Echezona A Methods Microbiol. 2024; 50:151-188.

PMID: 38620863 PMC: 9015106. DOI: 10.1016/bs.mim.2022.03.001.

Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in staff members of Bandar Abbas Children's Hospital.

Tariverdi M, Mohammadi H, Hassanzadeh F, Tamaddondar M BMC Infect Dis. 2024; 24(1):253.

PMID: 38395759 PMC: 10893658. DOI: 10.1186/s12879-023-08863-z.

References

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

Chan J, Yuan S, Kok K, To K, Chu H, Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514-523. PMC: 7159286. DOI: 10.1016/S0140-6736(20)30154-9. View

Escriou N, Callendret B, Lorin V, Combredet C, Marianneau P, Fevrier M . Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology. 2014; 452-453:32-41. PMC: 7111909. DOI: 10.1016/j.virol.2014.01.002. View

Folegatti P, Bittaye M, Flaxman A, Lopez F, Bellamy D, Kupke A . Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020; 20(7):816-826. PMC: 7172901. DOI: 10.1016/S1473-3099(20)30160-2. View

Liu R, Wu L, Huang B, Huang J, Zhang Y, Ke M . Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res. 2005; 112(1-2):24-31. PMC: 7114075. DOI: 10.1016/j.virusres.2005.02.009. View

Netland J, DeDiego M, Zhao J, Fett C, Alvarez E, Nieto-Torres J . Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology. 2010; 399(1):120-128. PMC: 2830353. DOI: 10.1016/j.virol.2010.01.004. View

Marohn M, Barry E . Live attenuated tularemia vaccines: recent developments and future goals. Vaccine. 2013; 31(35):3485-91. PMC: 3766925. DOI: 10.1016/j.vaccine.2013.05.096. View

Jiang S, He Y, Liu S . SARS vaccine development. Emerg Infect Dis. 2005; 11(7):1016-20. PMC: 3371787. DOI: 10.3201/1107.050219. View

Chen W, Strych U, Hotez P, Bottazzi M . The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020; 7(2):61-64. PMC: 7094941. DOI: 10.1007/s40475-020-00201-6. View

10.

Tang L, Wang J, Qin E, Zhu Q, Yu M, Ding Z . Preparation, characterization and preliminary studies of inactivated SARS-CoV vaccine. Chin Sci Bull. 2020; 48(23):2621-2625. PMC: 7088751. DOI: 10.1360/03wc464. View

11.

Pallesen J, Wang N, Corbett K, Wrapp D, Kirchdoerfer R, Turner H . Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017; 114(35):E7348-E7357. PMC: 5584442. DOI: 10.1073/pnas.1707304114. View

12.

Bukreyev A, Lamirande E, Buchholz U, Vogel L, Elkins W, St Claire M . Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004; 363(9427):2122-7. PMC: 7112367. DOI: 10.1016/S0140-6736(04)16501-X. View

13.

Nieto-Torres J, DeDiego M, Verdia-Baguena C, Jimenez-Guardeno J, Regla-Nava J, Fernandez-Delgado R . Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014; 10(5):e1004077. PMC: 4006877. DOI: 10.1371/journal.ppat.1004077. View

14.

Kim E, Erdos G, Huang S, Kenniston T, Balmert S, Donahue Carey C . Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 2020; 55:102743. PMC: 7128973. DOI: 10.1016/j.ebiom.2020.102743. View

15.

Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S . A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004; 16(10):1423-30. PMC: 7108621. DOI: 10.1093/intimm/dxh143. View

16.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

17.

Lu B, Tao L, Wang T, Zheng Z, Li B, Chen Z . Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice. Clin Vaccine Immunol. 2008; 16(1):73-7. PMC: 2620671. DOI: 10.1128/CVI.00261-08. View

18.

Wang Y, Sin W, Xu G, Yang H, Wong T, Pang X . T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J Virol. 2004; 78(11):5612-8. PMC: 415819. DOI: 10.1128/JVI.78.11.5612-5618.2004. View

19.

Stauffer F, El-Bacha T, Da Poian A . Advances in the development of inactivated virus vaccines. Recent Pat Antiinfect Drug Discov. 2008; 1(3):291-6. DOI: 10.2174/157489106778777673. View

20.

Kalita P, Padhi A, Zhang K, Tripathi T . Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog. 2020; 145:104236. PMC: 7196559. DOI: 10.1016/j.micpath.2020.104236. View